Huiyu Pharmaceuticals (688553.SH): Injection of Gefitinib Hydrochloride obtained drug registration certificate.

Huiyu Pharmaceuticals (688553.SH) announced that the company recently received the "Drug Registration Certificate" for injection of Gemcitabine hydrochloride approved and issued by the National Medical Products Administration. Gemcitabine hydrochloride (dFdC), a pyrimidine antimetabolite, is metabolized in cells by the action of nucleoside kinase to active di-phosphate (dFdCDP) and tri-phosphate nucleosides (dFdCTP). dFdCDP and dFdCTP inhibit DNA synthesis through two mechanisms to achieve the cytotoxic effect of Gemcitabine. This product can be used to treat the following diseases: -locally advanced or metastatic non-small cell lung cancer; -Gemcitabine in combination with Cetuximab and platinum-based chemotherapy is suitable for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer that is not eligible for surgical resection; -locally advanced or metastatic pancreatic cancer; -Gemcitabine in combination with Paclitaxel can be used to treat recurrent breast cancer after adjuvant/neoadjuvant chemotherapy, which cannot be removed, locally recurrent, or metastatic. Unless contraindicated clinically, anthracycline antibiotics should have been used in previous chemotherapy.